Nasz Lekarz Przychodnie Medyczne Sp. z o.o.
- Address
- lock Available on a paid plan
Hematologic Oncology and Infection Prevention
At Nasz Lekarz Przychodnie Medyczne Sp. z o.o. in Torun, clinical research is focused on neoplasms linked to blood cancers and the prevention of serious infections. The main diseases studied include chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma, with attention to patients who have weakened immune defenses.
- Evaluating a new supportive treatment to help reduce major bacterial infections in patients with B-cell chronic lymphocytic leukemia, multiple myeloma, and non-Hodgkin lymphoma
- Focusing on immune system protection and better infection control for people with hypogammaglobulinemia
- Supporting research that may improve the safety and daily care of patients receiving treatment for blood-related cancers
This area of research combines hematologic cancer care with microbiological phenomena and broader physiological processes, aiming to make treatment safer and reduce infection-related complications.
Advanced Prostate Cancer Research
The site is also involved in research on reproductive and urinary physiological phenomena through studies in metastatic hormone-sensitive prostate cancer. These trials are centered on patients with PTEN deficiency, a biological feature that can influence how the disease behaves and responds to therapy.
- Comparing a new treatment approach with standard care to see whether it can better delay radiographic progression in prostate cancer
- Studying whether targeted therapy can improve outcomes for men with PTEN-deficient disease
- Contributing to efforts that refine treatment effectiveness in advanced oncology
This research reflects a strong interest in cancer treatment innovation, with the goal of improving disease control and helping doctors choose more effective therapies for patients with advanced prostate cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 2 of 4 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Grifols Therapeutics LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nasz Lekarz Przychodnie Medyczne Sp. z o.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abiraterone Acetate | 1 | Unknown | 2020-09-18 | 2020-09-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.